Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Emotions From Salivary Biomarkers in an Architectural Context

NCT07507266 · tracked via the Priya Life Science France tracker
Sponsor
Phase
Observational
Started
2026-06-09
Last updated
2026-04-14

Condition(s) studied

Emotions

Investigational drug(s) / intervention(s)

Bio-fluid analysis for the measurement of salivary biomarkers linked to emotions

Bio-fluid analysis for the measurement of salivary biomarkers linked to emotions: Saliva of participants will be sampled for analysis of biomarkers of interest (DHEA, oxytocin, cortisol, alpha-amylase, serotonin, and dopamine) using enzymatic dosage methods or ELISA-type methods carried out using commercial kits.

Study summary

Architecture influences our well-being. People's behavior and mood changes in different spaces are directly related to the architectural qualities of the built environment. Neuroarchitecture is a discipline that combines neuroscience and architecture to design spaces adapted to the psychological and physiological needs of users. Several studies related to neuroarchitecture have been conducted according to different architectural parameters such as style, natural environment, lighting, color, and sunlight pattern. Recent studies show that emotional states can be evaluated by physiological responses. This physiological regulation comes from the action of enzymes and hormones that represent the activity of the autonomic nervous system. Measuring specific biomarkers through non-invasive biological tests in saliva provides physiological data on an individual's emotional state in response to stimuli, particularly visual or tactile.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Subject over 18 years old * Subject agreeing to follow the study procedures * Subject capable of understanding the purpose, nature, and methodology of the study * Subject affiliated with a French social security scheme or beneficiary of such a scheme. Exclusion Criteria: * Subject not affiliated with a French Social Security scheme or not a beneficiary of such a scheme * Subject deprived of liberty, protected adult, vulnerable person, or minor * Subject with proven or suspected chronic infectious disease that could pose a risk of contamination during sample handling (laboratories not equipped to handle this type of sample) * Subject with a deficiency (vision, anosmia) preventing proper interaction with the architectural work * Subject presenting signs of active oral inflammation, advanced periodontitis, or severe gingivitis * Subject suffering from Gougerot-Sjögren syndrome (dry syndrome) or mouth cancer * Pregnant or breastfeeding women.

Primary outcome measure(s)

  • Evaluate the variation of salivary biomarkers, which may be linked to emotions (positive or negative), before and after interaction with an architectural work. — 2 years
    Evaluate the variation of salivary biomarkers, which may be linked to emotions (positive or negative), before and after interaction with an architectural work. This exposure includes a combination of visual, tactile, and/or olfactory stimuli.

Trial sites (1)

FacilityCityRegionStatus
Sys2Diag - Umr9005 Cnrs/Alcen Montpellier France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07507266 on ClinicalTrials.gov ↗ ← All trials in France